公开(公告)号：US11266777B2

公开(公告)日：2022-03-08

申请号：US16071873

申请日：2017-02-13

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon B. Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Sean M. O'connor ,  Robert Decker ,  Gautam N. Shetty ,  Ryan M. Agard ,  Nicholas J. Ciccarelli ,  Daniel Davenport

IPC: A61M5/142 ,  A61M5/145 ,  A61M5/315 ,  A61M5/24

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

公开(公告)号：US12053618B2

公开(公告)日：2024-08-06

申请号：US16761149

申请日：2018-11-06

Applicant: AMGEN INC.

Inventor： Justin Harris ,  Matthew Wayne Janke ,  Wael Mismar ,  Jerome Olivas ,  Thomas Clark Pearson ,  Sudeshna Dutta Ray ,  Ryan M. Agard ,  Alexis Dechelette ,  Michael Gammelager ,  Mads Hansen ,  Valerio Mazzon ,  Owen Ryan ,  Clive Smith

IPC: A61M5/28 ,  A61M5/178 ,  A61M5/24 ,  A61M5/31

CPC classification number: A61M5/28 ,  A61M5/1782 ,  A61M5/24 ,  A61M5/3134 ,  A61M2005/2488 ,  A61M2005/3115

Abstract: Fill-finish assemblies facilitating the manufacture of a drug delivery device are disclosed. The fill-finish assembly may include a container, an insertion mechanism, a fluid pathway connection assembly disposed between the container and the insertion mechanism, and a carrier. The insertion mechanism may include a delivery member and an insertion mechanism housing. The insertion mechanism may be configured to move the delivery member from a retracted position inside the insertion mechanism housing to a deployed position outside the insertion mechanism housing. The fluid pathway connection assembly may be selectively activatable to establish fluid communication between the container and the delivery member. The carrier may have a hollow interior containing at least a portion of each of the container, the insertion mechanism, and the fluid pathway connection assembly. The carrier may be configured to hold the container, the insertion mechanism, and the fluid pathway connection assembly in alignment with each other.

公开(公告)号：US20220218900A1

公开(公告)日：2022-07-14

申请号：US17688578

申请日：2022-03-07

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon B, Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Sean M. O'connor ,  Robert Decker ,  Gautam N. Shetty ,  Ryan M. Agard ,  Nicholas J. Ciccarelli ,  Daniel Davenport

IPC: A61M5/142 ,  A61M5/145 ,  A61M5/315

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

公开(公告)号：US20200338271A1

公开(公告)日：2020-10-29

申请号：US16761149

申请日：2018-11-06

Applicant: AMGEN INC.

Inventor： Justin Harris ,  Matthew Wayne Janke ,  Wael Mismar ,  Jerome Olivas ,  Thomas Clark Pearson ,  Sudeshna Dutta Ray ,  Ryan M. Agard ,  Alexis Dechelette ,  Michael Gammelager ,  Mads Hansen ,  Valerio Mazzon ,  Owen Ryan ,  Clive Smith

IPC: A61M5/28 ,  A61M5/31 ,  A61M5/24 ,  A61M5/178

Abstract: Fill-finish assemblies facilitating the manufacture of a drug delivery device are disclosed. The fill-finish assembly may include a container, an insertion mechanism, a fluid pathway connection assembly disposed between the container and the insertion mechanism, and a carrier. The insertion mechanism may include a delivery member and an insertion mechanism housing. The insertion mechanism may be configured to move the delivery member from a retracted position inside the insertion mechanism housing to a deployed position outside the insertion mechanism housing. The fluid pathway connection assembly may be selectively activatable to establish fluid communication between the container and the delivery member. The carrier may have a hollow interior containing at least a portion of each of the container, the insertion mechanism, and the fluid pathway connection assembly. The carrier may be configured to hold the container, the insertion mechanism, and the fluid pathway connection assembly in alignment with each other.